ProCE Banner Activity

Phase II KEYNOTE-170/KEYNOTE-013 Update: Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma

Slideset Download
Conference Coverage
In a combined analysis of KEYNOTE-013 and KEYNOTE-170, relapsed/refractory PMBCL patients who received pembrolizumab showed durable responses, with more than one half of patients alive at 1 year.

Released: December 06, 2018

Expiration: December 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology